Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,252.80
(
-1.87%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
106.70
(
0.00%
)
Bitcoin
79,079.72
(
0.03%
)
News Focus
News Focus
Post# of 257578
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 156902

Thursday, 10/06/2016 10:02:01 AM

Thursday, October 06, 2016 10:02:01 AM

Post# of 257578
TEVA, Celltrion ink FoB collaboration for Rituxan/Herceptin in US/Canada:

http://finance.yahoo.com/news/teva-celltrion-announce-exclusive-biosimilar-120000044.html

This is essentially a booby price for TEVA, who has been actively searching for a global FoB partner. Celltrion’s FoB programs for Rituxan and Herceptin were returned by PFE in 2015 as a consequence of PFE’s merger with HSP (http://www.fiercebiotech.com/r-d/pfizer-cuts-some-biosimilar-ties-celltrion-after-its-17b-hospira-deal ).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today